Search hospitals > Maryland > Berlin
TidalHealth Richard A Henson Cancer Institute
Claim this profileBerlin, Maryland 21811
Global Leader in Cancer
Conducts research for Lung Cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Breast Cancer
Conducts research for Adenocarcinoma
20 reported clinical trials
4 medical researchers
Summary
TidalHealth Richard A Henson Cancer Institute is a medical facility located in Berlin, Maryland. This center is recognized for care of Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Breast Cancer, Adenocarcinoma and other specialties. TidalHealth Richard A Henson Cancer Institute is involved with conducting 20 clinical trials across 73 conditions. There are 4 research doctors associated with this hospital, such as Justinian R. Ngaiza, John R. Mansueti, Zeinab Abou Yehia, and Justin R. Kucinski.Area of expertise
1Cancer
Global LeaderStage II
Stage I
Stage IV
2Lung Cancer
Stage II
Stage IV
Stage I
Top PIs
Justinian R. NgaizaTidalHealth Richard A Henson Cancer Institute9 years of reported clinical research
Studies Non-Small Cell Lung Cancer
Studies Lung Cancer
4 reported clinical trials
5 drugs studied
John R. MansuetiTidalHealth Richard A Henson Cancer Institute7 years of reported clinical research
Studies Adenocarcinoma
Studies Prostate Cancer
3 reported clinical trials
9 drugs studied
Zeinab Abou YehiaTidalHealth Richard A Henson Cancer Institute3 years of reported clinical research
Studies Cancer
Studies Small Cell Carcinoma
2 reported clinical trials
5 drugs studied
Justin R. KucinskiTidalHealth Richard A Henson Cancer Institute4 years of reported clinical research
Studies Squamous Cell Carcinoma
Studies Non-Small Cell Lung Cancer
1 reported clinical trial
5 drugs studied
Clinical Trials running at TidalHealth Richard A Henson Cancer Institute
Lung Cancer
Non-Small Cell Lung Cancer
Small Cell Lung Cancer
Cancer
Squamous Cell Carcinoma
ALK Gene Rearrangement
Small Cell Carcinoma
Brain Metastasis
Tumors
Immunotherapy + Chemotherapy
for Non-Small Cell Lung Cancer
This phase III ALCHEMIST trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB, IIIA or IIIB non-small cell lung cancer.
Recruiting2 awards Phase 327 criteria
Crizotinib
for Non-Small Cell Lung Cancer
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.
Recruiting2 awards Phase 328 criteria
Stereotactic Radiosurgery vs Whole-Brain Radiotherapy
for Brain Metastasis from Lung Cancer
This phase III trial compares the effect of stereotactic radiosurgery to standard of care memantine and whole brain radiation therapy that avoids the hippocampus (the memory zone of the brain) for the treatment of small cell lung cancer that has spread to the brain. Stereotactic radiosurgery is a specialized radiation therapy that delivers a single, high dose of radiation directly to the tumor and may cause less damage to normal tissue. Whole brain radiation therapy delivers a low dose of radiation to the entire brain including the normal brain tissue. Hippocampal avoidance during whole-brain radiation therapy (HA-WBRT) decreases the amount of radiation that is delivered to the hippocampus which is a brain structure that is important for memory. The drug, memantine, is also often given with whole brain radiotherapy because it may decrease the risk of side effects related to thinking and memory. Stereotactic radiosurgery may decrease side effects related to memory and thinking compared to standard of care HA-WBRT plus memantine.
Recruiting2 awards Phase 315 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at TidalHealth Richard A Henson Cancer Institute?
TidalHealth Richard A Henson Cancer Institute is a medical facility located in Berlin, Maryland. This center is recognized for care of Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Breast Cancer, Adenocarcinoma and other specialties. TidalHealth Richard A Henson Cancer Institute is involved with conducting 20 clinical trials across 73 conditions. There are 4 research doctors associated with this hospital, such as Justinian R. Ngaiza, John R. Mansueti, Zeinab Abou Yehia, and Justin R. Kucinski.